

Linshom Medical Receives \$100K MIPS award to Launch a Clinical Trial with the University of Maryland School of Medicine

BALTIMORE, MD, UNITED STATES, August 6, 2026 /EINPresswire.com/ -- Linshom Medical announced today that it has been awarded a \$100,000 Phase 2 grant from the Maryland Industrial Partnerships (MIPS) program to support an interventional clinical trial of its respiratory monitoring device, led by faculty from the University of Maryland School of Medicine (UMSOM).

"This clinical trial is an extension of a Phase 1 clinical study completed last year and will evaluate the device's ability to drive early intervention of patient respiratory decline in the Post Anesthesia Care Unit (PACU)," said Donald R. Herdt, MD, MBA, principal investigator and assistant professor of anesthesiology at UMSOM. "The Phase 1 study demonstrated the device's ability to detect respiratory depression episodes (RDEs) 25 minutes before current standard of care. Now, we will measure the effect of early intervention."

"Current standard of care and existing technology provide warnings after a patient is in respiratory trouble," said Richard Huguen, chief executive officer of Linshom Medical. "If we are able to provide early or predictive notice of respiratory decline, health care providers should be able to intervene and avoid costly events like rapid response activations, rescue events (codes), and intensive care unit transfers."



MIPS provides matching grants for collaborative research projects between Maryland-based companies and University System of Maryland institutions. The grants are awarded on a competitive basis and are based on proposals submitted jointly by participating companies and university researchers.

About Linshom Medical, Inc.

Linshom Medical is first to deliver an AI enabled, wearable, FDA cleared, operating room quality respiratory profile to the patient bedside providing early warning of respiratory problems and avoiding costly rapid response activations, rescue events (codes), ICU transfers and deaths. The patented device provides a predictive (vs. responsive) respiratory profile including Respiratory Rate (RR), relative Tidal Volume (rVt) and Seconds Since Last Breath (SSLB) that are all delivered continuously and in real time. Our mission is to eliminate the morbidity, mortality and cost due to unrecognized respiratory compromise in healthcare. For more information, visit www.LinshomMedical.com.

About Maryland Industrial Partnerships (MIPS)

The Maryland Industrial Partnerships (MIPS) program is an initiative of the Maryland Technology Enterprise Institute (Mtech) in the A. James Clark School of Engineering at the University of Maryland. MIPS funds university research projects that team faculty with Maryland-based companies to develop technology products and processes. Both the company and MIPS provide funds for each project. All funds go to the university researchers. www.mips.umd.edu

Richard Huguen

Linshom Medical, Inc.

[email us here](#)

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/932036971>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.